By Giulia Petroni

Sanofi SA said late Monday that it has finalized the restructuring of the antibody collaboration for cholesterol treatment Praluent with Regeneron Pharmaceuticals Inc.

The French drug maker said that, starting from April 1, it will supply the alirocumab drug outside the U.S. and Regeneron will supply it in the U.S.

The companies, however, have entered into agreements to support manufacturing needs in the near term.

Sanofi and Regeneron announced their intent to restructure the antibody collaboration for Praluent in December 2019.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

April 07, 2020 01:54 ET (05:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Regeneron Pharmaceuticals Charts.